Viewpoint News & Awards

Viewpoint identified in “Best University Startups 2016” in the United States

August 31, 2016 (Coralville, IA) – Viewpoint Molecular Targeting, LLC has been identified as one of the “Best University Startups 2016” by the National Council on Entrepreneurial Tech Transfer (NCET2) and was one of 35 companies invited to present at the NCET2 National Demo Day in Washington, D.C. on September 20th.

NCET2 University Startups Demo Day highlights universities’ success in constructing cross-campus “innovation ecosystems”. It is estimated that over 800 startups are created in universities annually and 200 of those companies were considered for this event. “Viewpoint clearly stands out as having an exceptional blend of innovative biomedical technology and business leadership that will take the company to the next level” says NCET2 Associate Director Ria Ancheta-Adrias.  “The team was an obvious choice for a Best University Startup 2016 designation”.

Viewpoint has been selected based on the commercialization potential of its technology; recent successes in securing Small Business Innovation Research grant funding from the National Institutes of Health; and strength of its business plan for growing the company. “We are absolutely delighted” says Co founder and Chief Science Officer Michael K Schultz. “The selection to the list of Best Startups is further evidence that we are making sound business decisions and are being recognized for it.”

Viewpoint Molecular Targeting is developing pharmaceutical drugs for diagnostic imagining and therapy for cancer, with a focus on metastatic melanoma, and is located in the UI BioVentures Center. Viewpoint has successfully secured over $1.2Mln through NIH SBIR grants; Iowa Economic Development Authority Demonstration Funds; Innovation Iowa Corporation Matching Funds; and contracts to pharmaceutical industry partners. The company is aiming to begin clinical trials for its lead product and has other products in the development pipeline.

“Our technology has the potential to save lives” says Co-founder and Chief Medical Officer Frances L Johnson “The selection by NCET2 to present at Demo Day, gives us another great opportunity to make that a reality and we’re excited.”

“Viewpoint continues to make exceptional progress in building a company that is positioned for growth” says Paul Dymerski, Director for New Ventures at the University of Research Foundation

See more: OVPR-EDIowa Biotech AssociationUI Health Care

 

usdd_badge

Viewpoint’s products are currently under development and therefore not approved by the FDA.